BioCentury
ARTICLE | Company News

Genzyme's Thyrogen facing supply shortage

March 19, 2011 12:19 AM UTC

EMA's CHMP said Genzyme Corp. (NASDAQ:GENZ) notified the committee that due to a manufacturing issue the biotech will be able to meet only about 45% of European demand for thyroid cancer treatment Thyrogen thyrotropin alfa until July. Genzyme said it identified a processing problem in a batch of Thyrogen intended for the European market prior to the fill/finish process at one of its manufacturing plants in Framingham, Mass. Genzyme added that the shortage also will affect U.S. supplies of Thyrogen from mid-April through mid-July to an undisclosed extent. Genzyme said the issue did not occur at its newest plant in Framingham, Mass. Genzyme is being acquired by sanofi-aventis Group (Euronext:SAN; NYSE:SNY). Genzyme was off $0.17 to $75.59 on Friday. ...